Penumbra Inc (NYSE:PEN) target price raised to $80.00, issued a research note today by Zacks Investment Research
- Updated: October 15, 2016
Just yesterday Penumbra Inc (NYSE:PEN) traded -0.48% lower at $71.74. Penumbra Inc’s 50-day moving average is $73.25 and its 200-day moving average is $61.93. The last closing price is up 14.53% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 111,403 shares of PEN traded hands, down from an average trading volume of 252,585
In a report released on 10/13/2016 Zacks Investment Research increased the stock price target of Penumbra Inc (NYSE:PEN) to $80.00 reporting a possible upside of 0.12%.
Previously on 10/13/2015, Canaccord Genuity reported on Penumbra Inc (NYSE:PEN) increased the target price from $0.00 to $48.00. At the time, this indicated a possible upside of 0.23%.
Recent Performance Chart
Penumbra Inc has 52 week low of $35.31 and a 52 week high of $79.49 with a P/E ratio of 921.17 and has a market cap of $0.
General Information About Penumbra Inc (NYSE:PEN)
Penumbra, Inc. (Penumbra) is an interventional therapies company. The Company designs, develops, manufactures and markets medical devices. The Company has a portfolio of products that addresses medical conditions and significant clinical needs across two markets, neuro and peripheral vascular. The conditions that its products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures. The Company focuses on developing, manufacturing and marketing products for use by specialist physicians, including interventional neuroradiologists, neurosurgeons, interventional neurologists, interventional radiologists and vascular surgeons. Its neuro products include Neurovascular Access, Ischemic Stroke, Neurovascular Embolization and Neurosurgical Tools. The Company's peripheral vascular products include Peripheral Embolization and Peripheral Thrombectomy.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.